Mesa Laboratories, Inc. — Form 10-Q Summary
Reporting period: Three months ended June 30, 2022, Mesa’s first quarter of fiscal 2023. The request metadata identifies “2021 Q1,” but the filing itself reports fiscal 2023 results and compares them with the three months ended June 30, 2021.
Business context
Mesa manufactures, develops, and sells life science tools and critical quality-control products and services through four reportable segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment reflects the Agena Bioscience acquisition completed October 20, 2021.
Key financial metrics
| Metric | Q1 FY2023 | Q1 FY2022 | Change |
|---|---|---|---|
| Revenue | $50.453 million | $34.920 million | +44% |
| Gross profit | $31.341 million | $22.211 million | +41% |
| Gross margin | 62.1% | 63.6% | Down approximately 2 percentage points |
| Operating expenses | $35.935 million | $19.088 million | +88% |
| Operating income (loss) | $(4.594) million | $3.123 million | Declined $7.717 million |
| Net income (loss) | $(1.438) million | $1.995 million | Declined $3.433 million |
| Basic and diluted EPS | $(0.27) | $0.39 / $0.38 | Turned negative |
| Cash flow from operations | $(2.811) million | $9.589 million | Declined $12.400 million |
Organic revenue growth was 3%, with reported growth primarily driven by Agena. Segment revenue was $14.505 million for Clinical Genomics, $14.774 million for Sterilization and Disinfection Control, $10.967 million for Biopharmaceutical Development, and $10.207 million for Calibration Solutions.
As of June 30, 2022, cash and cash equivalents were $43.747 million, working capital was $84.0 million, total assets were $685.811 million, and total liabilities were $305.380 million. Inventory increased to $26.874 million from $24.606 million at March 31, 2022, primarily as the company built raw-material stocks to mitigate supply constraints.
Debt included $47.0 million outstanding under the Credit Facility and $172.5 million principal amount of 1.375% convertible senior notes due August 2025, carried at $169.590 million. The company was in compliance with all Credit Facility covenants at June 30, 2022. Mesa repaid an additional $12.0 million under the Credit Facility in July 2022.
Material changes versus the prior comparable period
- Revenue increased 44%, primarily from the Agena acquisition; organic revenue increased 3%.
- Gross margin declined from approximately 64% to 62%, reflecting supply-chain constraints, labor and other inflationary pressures, foreign-exchange effects, and COVID-19-related shutdowns.
- Operating expenses rose sharply because of Agena, higher selling and administrative costs, increased research and development spending, stock-based compensation, and amortization of acquired intangibles.
- Clinical Genomics contributed $14.505 million of revenue and $7.849 million of gross profit, but results were negatively affected by COVID-19 shutdowns in parts of China.
- Biopharmaceutical Development revenue increased 24% and gross margin improved to 65% from 53%, aided by product mix, production efficiencies, and foreign-exchange effects.
- Sterilization and Disinfection Control revenue declined 2% and gross margin declined to 73% from 75%, primarily because of labor shortages, higher labor costs, and a stronger U.S. dollar against the euro.
- Calibration Solutions revenue declined 6% because supply constraints limited production of certain products; gross margin declined to 55% from 56%.
- Comprehensive loss was $17.395 million, including a $15.957 million unfavorable foreign-currency translation adjustment, compared with comprehensive income of $7.366 million in the prior-year quarter.
Cash flow, liquidity, outlook, and risks
Operating cash flow was negative because of the net loss, bonus payments accrued at year-end, increased inventories, prepaid insurance and other annual renewals. Investing cash outflow was $0.225 million, primarily for property and equipment. Financing cash outflow was $1.407 million, including $2.0 million of debt repayment and $0.843 million of dividends, partly offset by $1.436 million from stock-option exercises.
Management stated that operating cash flows, cash on hand, Credit Facility availability, and potential equity issuance are expected to fund ongoing operations, interest, dividends, and anticipated capital expenditures. In April 2022, Mesa entered an Open Market Sale Agreement allowing potential sales of up to $150 million of common stock.
Management expected supply-chain constraints to abate somewhat during the remainder of fiscal 2023, but noted continuing risks from inflation, labor shortages, material availability, foreign-currency movements, and COVID-19 disruptions. Additional price increases were scheduled to take effect in the second quarter of fiscal 2023. Labor shortages, particularly in Sterilization and Disinfection Control, could affect manufacturing timelines, revenue, and gross profit.
The filing provides no formal quantitative revenue or earnings guidance. Mesa reported approximately $24.081 million of open purchase orders for routine supplies and inventory, payable within one year. No material legal reserves or off-balance-sheet arrangements were reported.
Other unusual items included $7.320 million of amortization of acquisition-related intangible assets, $3.432 million of stock-based compensation expense, a preliminary Agena purchase-price allocation, and significant foreign-currency translation losses. The effective tax rate was unusually negative because of share-based payment effects and the geographic mix of earnings.
Important facts for investors to verify
- Confirm the applicable period: the filing is for June 30, 2022, or Q1 fiscal 2023, rather than Q1 2021.
- Assess whether Agena integration, acquisition-related amortization, and elevated operating expenses can be absorbed while maintaining margins.
- Monitor organic growth separately from acquisition-driven revenue growth.
- Evaluate supply-chain and labor constraints, inventory growth, pricing actions, and their effect on gross margin and cash conversion.
- Review liquidity and leverage after the July 2022 $12.0 million debt repayment, including the $172.5 million convertible notes due in 2025.
- Consider exposure to foreign-currency volatility, particularly because Mesa does not hedge exchange-rate exposure.
- Review the potential dilution and financing implications of the $150 million at-the-market equity-sale authorization.
- Verify future COVID-19 effects in China and other geographic markets, as well as the company’s ability to recover Clinical Genomics demand.